In February, had the firm withdrawn an application for emergency-use authorisation of its vaccine in India, after failing to meet the drug regulator’s demand for a local safety and immunogenicity study. Now, as per a new rule, the company is eligible to directly seek EUA from the Drugs Controller General of India.Exclusive: Pfizer says will continue to engage with govt to make its COVID-19 vaccine available in India
In February, had the firm withdrawn an application for emergency-use authorisation of its vaccine in India, after failing to meet the drug regulator’s demand for a local safety and immunogenicity study. Now, as per a new rule, the company is eligible to directly seek EUA from the Drugs Controller General of India.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment